Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Adopting the New Therapeutic “LineUp” to Manage ASCVD - East
Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.
Live
Meeting
3.50 available credits
Information
February 04, 2022
07:45 AM - 12:00 PM EST
Hyatt Regency Sarasota
1000 Boulevard of the Arts, Sarasota, Florida, United States
Hyatt Regency Sarasota
Share
Share
Share this program on:
Details
Presenters
Related
Comments
Program Schedule*
Click Here to Download Slide Presentation
7:45 am–8:30 am
Registration and Breakfast
8:30 am–8:35 am
Welcome, Introductions, Program Overview
Michael Miller, MD
Program Chair8:35 am–8:45 am
Burden of Heart Disease Today
James Underberg, MD8:45 am–9:15 am
Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
Aruna Pradhan, MD9:15 am–9:45 am
REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
Michael Miller, MD9:45 am–10:00 am
Panel Discussion
All faculty10:00 am–10:15 am
Break
10:15 am–10:30 am
Recent Evidence from REDUCE-IT Sub-studies
Michael Miller, MD10:30 am–11:00 am
Differential Biological Effects of Omega-3 Fatty Acids
James Underberg, MD11:00 am–11:20 am
Role of Pharmacist in Establishing Lipid Intervention
Mary Katherine Cheeley, PharmD11:20 am–11:35 am
11:35 am–11:55 am
Panel Discussion
All Faculty
Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
All Faculty11:55 am–12:00 pm
Closing Comments, Adjourn
Michael Miller, MD*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Michael Miller, MD, FACC, FAHA
Chief of Medicine
Corporal Michael J. Crescenz VAMC;
Professor and Vice Chair of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA
Consulting Fees: Amarin, Pfizer, 89BioFaculty:
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Clinical Pharmacist Specialist, Primary Care
Grady Health System
Atlanta, GA
No relationship reportedAruna Pradhan, MD, MPH
Assistant Professor of Medicine
Harvard Medical School;
Associate Physician
Scientific Director, Preventive Medicine Cohorts Biorepository
Division of Preventive Medicine
Brigham and Women's Hospital
Boston, MA
Consulting Fees: Novo Nordisk
Contracted Research: Kowa Research InstituteJames Underberg, MD, MS, FACP, FNLA
Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease;
Director, Bellevue Hospital Lipid Clinic;
Past President, National Lipid Association
New York, NY
Consulting Fees: Amgen, Esperion, Novartis
Speakers Bureau: Alexion, Amarin, Amgen, Amyrt Pharma, Esperion
Contracted Research: Amyrt PharmaReviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Mario Trucillo, PhD, MS has nothing to disclose.
- Kathy Wickman has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
- Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
- Identify barriers to the implementation of effective, long-term management of ASCVD
Target Audience
This activity is designed to meet the educational needs of primary care physicians and community pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
Presenters
Related
Details
Presenters
Related
Comments
Overview
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Program Schedule*
Click Here to Download Slide Presentation
7:45 am–8:30 am
Registration and Breakfast
8:30 am–8:35 am
Welcome, Introductions, Program Overview
Michael Miller, MD
Program Chair8:35 am–8:45 am
Burden of Heart Disease Today
James Underberg, MD8:45 am–9:15 am
Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
Aruna Pradhan, MD9:15 am–9:45 am
REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
Michael Miller, MD9:45 am–10:00 am
Panel Discussion
All faculty10:00 am–10:15 am
Break
10:15 am–10:30 am
Recent Evidence from REDUCE-IT Sub-studies
Michael Miller, MD10:30 am–11:00 am
Differential Biological Effects of Omega-3 Fatty Acids
James Underberg, MD11:00 am–11:20 am
Role of Pharmacist in Establishing Lipid Intervention
Mary Katherine Cheeley, PharmD11:20 am–11:35 am
11:35 am–11:55 am
Panel Discussion
All Faculty
Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
All Faculty11:55 am–12:00 pm
Closing Comments, Adjourn
Michael Miller, MD*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Michael Miller, MD, FACC, FAHA
Chief of Medicine
Corporal Michael J. Crescenz VAMC;
Professor and Vice Chair of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA
Consulting Fees: Amarin, Pfizer, 89BioFaculty:
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Clinical Pharmacist Specialist, Primary Care
Grady Health System
Atlanta, GA
No relationship reportedAruna Pradhan, MD, MPH
Assistant Professor of Medicine
Harvard Medical School;
Associate Physician
Scientific Director, Preventive Medicine Cohorts Biorepository
Division of Preventive Medicine
Brigham and Women's Hospital
Boston, MA
Consulting Fees: Novo Nordisk
Contracted Research: Kowa Research InstituteJames Underberg, MD, MS, FACP, FNLA
Clinical Lipidology
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease;
Director, Bellevue Hospital Lipid Clinic;
Past President, National Lipid Association
New York, NY
Consulting Fees: Amgen, Esperion, Novartis
Speakers Bureau: Alexion, Amarin, Amgen, Amyrt Pharma, Esperion
Contracted Research: Amyrt PharmaReviewers/Content Planners/Authors:
- Sean T. Barrett has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Mario Trucillo, PhD, MS has nothing to disclose.
- Kathy Wickman has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
- Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
- Identify barriers to the implementation of effective, long-term management of ASCVD
Target Audience
This activity is designed to meet the educational needs of primary care physicians and community pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
Presenters
Facebook Comments